RecruitingNCT06508710
Ketamine or placebo with venlafaxine for severe depression
About this title
Read the official source — NCT06508710Medication studyAges 18–65France
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
What will I do during this study?
Depending on the group, the protocol specifies the study medication (ketamine) or a placebo (an inactive comparison treatment).
- Listed locations
- Le Kremlin-Bicêtre and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 20, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 60
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06508710
- Official title
Show the full official title
Early Efficacy of Ketamine Compared With Placebo as Adjunctive Therapy With Venlafaxine in Severely Unipolar Depressed Inpatients
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Le Kremlin-Bicêtre · Étampes · Orsay
Questions about this study
Who is behind this study?
The study sponsor is Assistance Publique - Hôpitaux de Paris.
Does this study involve medication?
Yes. The study involves medication, including ketamine and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
